(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

被引：727

作者：

Kim, D ^{[1
]}

Wang, LP ^{[1
]}

Beconi, M ^{[1
]}

Eiermann, GJ ^{[1
]}

Fisher, MH ^{[1
]}

He, HB ^{[1
]}

Hickey, GJ ^{[1
]}

Kowalchick, JE ^{[1
]}

Leiting, B ^{[1
]}

Lyons, K ^{[1
]}

Marsilio, F ^{[1
]}

McCann, ME ^{[1
]}

Patel, RA ^{[1
]}

Petrov, A ^{[1
]}

Scapin, G ^{[1
]}

Patel, SB ^{[1
]}

Roy, RS ^{[1
]}

Wu, JK ^{[1
]}

Wyvratt, MJ ^{[1
]}

Zhang, BB ^{[1
]}

Zhu, L ^{[1
]}

Thornberry, NA ^{[1
]}

Weber, AE ^{[1
]}

机构：

[1] Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 48卷 / 01期

关键词：

D O I：

10.1021/jm0493156

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A novel series of beta-amino amides incorporating fused heterocycles, i.e., triazolopiperazines, were synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of type 2 diabetes. (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (1) is a potent, orally active DPP-IV inhibitor (IC50 = 18 nM) with excellent selectivity over other proline-selective peptidases, oral bioavailability in preclinical species, and in vivo efficacy in animal models. MK-0431, the phosphate salt of compound 1, was selected for development as a potential new treatment for type 2 diabetes.

引用

收藏

页码：141 / 151

页数：11

相关论文

共 53 条

[31]

ORSKOV C, 1992, DIABETOLOGIA, V35, P701

[32] 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors [J].

Parmee, ER ;

He, JF ;

Mastracchio, A ;

Edmondson, SD ;

Colwell, L ;

Eiermann, G ;

Feeney, WP ;

Habulihaz, B ;

He, HB ;

Kilburn, R ;

Leiting, B ;

Lyons, K ;

Marsilio, F ;

Patel, RA ;

Petrov, A ;

Di Salvo, J ;

Wu, JK ;

Thornberry, NA ;

Weber, AE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (01) :43-46

[33] Aminomethylpyridines as DPP-IV inhibitors [J].

Peters, JU ;

Weber, S ;

Kritter, S ;

Weiss, P ;

Wallier, A ;

Zimmerli, D ;

Boehringer, M ;

Steger, M ;

Loeffler, BM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (13) :3579-3580

[34] An aminomethylpyrimidine DPP-IV inhibitor with improved properties [J].

Peters, JU ;

Hunziker, D ;

Fischer, H ;

Kansy, M ;

Weber, S ;

Kritter, S ;

Müller, A ;

Wallier, A ;

Ricklin, F ;

Boehringer, M ;

Poli, SM ;

Csato, M ;

Loeffler, BM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (13) :3575-3578

[35] Aminomethylpyrimidines as novel DPP-IV inhibitors:: A 105-fold activity increase by optimization of aromatic substituents [J].

Peters, JU ;

Weber, S ;

Kritter, S ;

Weiss, P ;

Wallier, A ;

Boehringer, M ;

Hennig, M ;

Kuhn, B ;

Loeffler, BM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (06) :1491-1493

[36] Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats [J].

Pospisilik, JA ;

Martin, J ;

Doty, T ;

Ehses, JA ;

Pamir, N ;

Lynn, FC ;

Piteau, S ;

Demuth, HU ;

McIntosh, CHS ;

Pederson, RA .

DIABETES, 2003, 52 (03) :741-750

[37] Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog [J].

Rasmussen, HB ;

Branner, S ;

Wiberg, FC ;

Wagtmann, N .

NATURE STRUCTURAL BIOLOGY, 2003, 10 (01) :19-25

[38] Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice [J].

Reimer, MK ;

Holst, JJ ;

Ahrén, B .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) :717-727

[39]

SCALLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657

[40] ASYMMETRIC SYNTHESES VIA HETEROCYCLIC INTERMEDIATES .6. ENANTIOSELECTIVE SYNTHESIS OF (R)-AMINO ACIDS USING L-VALINE AS CHIRAL AGENT [J].

SCHOLLKOPF, U ;

GROTH, U ;

DENG, C .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1981, 20 (09) :798-799

← 1 2 3 4 5 6 →